scholarly journals Clinical assessment and cytokines level in constipation-predominant irritable bowel syndrome participants treated with Lactobacillus-containing cultured milk drink

2021 ◽  
Vol 84 (4) ◽  
pp. 585-591
Author(s):  
N.M. Mokhtar ◽  
N.Md. Jaafar ◽  
E Alfian ◽  
N.D. Mohd Rathi ◽  
R Abdul Rani ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Lactobacillus Acidophilus ◽  
Clinical Symptoms ◽  
Adjunctive Treatment ◽  
Intestinal Transit Time ◽  
Gut Dysbiosis ◽  
Tnf Α ◽  
Fecal Ph ◽  
Irritable Bowel ◽  
Pro Inflammatory Cytokines

Gut dysbiosis is linked with the pathophysiology of irritable bowel syndrome (IBS). Manipulation of intestinal microbiota using cultured milk drinks may stimulate the immune system, hence providing beneficial support in IBS treatment. This study aimed to investigate the effects of cultured milk drink on clinical symptoms, intestinal transit time (ITT), fecal pH and cytokines in constipation- predominant IBS (IBS-C) as compared to non-IBS participants. Each recruited participant was given three bottles of 125 ml cultured milk drink containing 10 9 cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01 consumed daily for 30 days. At pre- and post-30-day consumption, fecal pH, ITT, clinical symptoms, IL-6, IL-8 and TNF-α levels were assessed. Seventy- seven IBS-C and 88 non-IBS were enrolled. Post-consumption, 97.4% of IBS-C experienced improvements in constipation- related symptoms supported by the significant reduction of ITT and decreased fecal pH (p<0.05). All pro-inflammatory cytokines were significantly lower in post as compared to pre-consumption of cultured milk drinks in IBS-C (p<0.05). There was significant reduction in the IL-8 and TNF-α levels in post- as compared to pre-consumption for the non-IBS (p < 0.05). Cultured milk drink taken daily improved clinical symptoms and reduced cytokines, hence should be considered as an adjunctive treatment in IBS-C individuals.

Gut dysbiosis and irritable bowel syndrome: The potential role of probiotics

2018 ◽  
Vol 76 (2) ◽  
pp. 111-120 ◽  
Author(s):  
Nicola Principi ◽  
Rita Cozzali ◽  
Edoardo Farinelli ◽  
Andrea Brusaferro ◽  
Susanna Esposito
Keyword(s):  
Irritable Bowel Syndrome ◽  
Potential Role ◽  
Gut Dysbiosis ◽  
Irritable Bowel

Association of Serum Vitamin D Concentration With Clinical Symptoms and Quality of Life in Patients With Irritable Bowel Syndrome

2018 ◽  
Vol 38 (4) ◽  
pp. 327-333 ◽  
Author(s):  
Amir Abbasnezhad ◽  
Reza Amani ◽  
Amin Hasanvand ◽  
Esmaeil Yousefi Rad ◽  
Meysam Alipour ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Vitamin D ◽  
Irritable Bowel Syndrome ◽  
Clinical Symptoms ◽  
Serum Vitamin ◽  
Serum Vitamin D ◽  
Irritable Bowel

Irritable bowel syndrome – a common problem, individual approach

2021 ◽  
Vol 14 (4) ◽  
pp. 369-374
Author(s):  
Barbara Skrzydło-Radomańska ◽  
Bartosz J. Sapilak
Keyword(s):  
Irritable Bowel Syndrome ◽  
Clinical Symptoms ◽  
Recurrent Abdominal Pain ◽  
Frequency Change ◽  
High Fiber ◽  
Fiber Diet ◽  
Bowel Movements ◽  
Irritable Bowel ◽  
Effective Drugs

Irritable bowel syndrome is a recurrent abdominal pain that occurs at least once a week for 3 months, with symptoms at least 6 months associated with at least two features: bowel movements, change in bowel frequency, change in the appearance of stools. According to the Rome IV Diagnostic Criteria, the disease is diagnosed on the basis of clinical symptoms. This does not apply to people over 50 years of age (and in the case of first-degree relatives of patients with colorectal cancer after 45 years of age) and patients with alarm symptoms. Due to the lack of a single etiological factor, the treatment of irritable bowel syndrome consists in reducing symptoms and improving the patient’s quality of life. Non-pharmacological treatment includes a high-fiber diet and modification of the microbiota. The most effective drugs are antispasmodics directly affecting the smooth muscle, inhibiting the influx of calcium, i.e. drotaverine, mebeverine and alverine. There has been proven effectiveness of antidepressants. This confirms that functional disorders of the gastrointestinal tract are a manifestation of the dysfunction of the brain–gut–microbiota axis.

scholarly journals Ginger relieves intestinal hypersensitivity of diarrhea predominant irritable bowel syndrome by inhibiting proinflammatory reaction

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Changrong Zhang ◽  
Yongquan Huang ◽  
Peiwu Li ◽  
Xinlin Chen ◽  
Fengbin Liu ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Hplc Analysis ◽  
Chemical Stimulation ◽  
Inflammatory Factors ◽  
Tnf Α ◽  
Defecation Frequency ◽  
Fecal Water ◽  
Intestinal Hypersensitivity ◽  
Irritable Bowel ◽  
Proinflammatory Factors

Abstract Background Ginger or ginger extracts have been used in traditional medicine relieve pain caused by diarrhea predominant irritable bowel syndrome (IBS-D), but few data exists about its effectiveness. This present study was to validate the effect of ginger on visceral pain, and to further explore the possible underlying mechanism by which ginger is used to relieve IBS-D intestinal hypersensitivity. Methods First, the IBS-D rat model was established by chemical stimulation and acute and chronic pressure stimulation. Then, different dose of ginger were administrated to IBS-D rats and evaluate the defecation frequency, fecal water content (FWC) and abdominal withdrawal reflex (AWR) scores in IBS-D rats. Further, the IBS-D rats were sacrificed to collecte the colonic tissues to evaluate the effect of ginger administration on its pathology and changes of pro-inflammatory factors, and changes of NF-κB pathway. Second, the ginger was taken to HPLC analysis and 6-gingerol was choosen to further experiment. Then, IBS-D rats were treated with different dose of 6-gingerol, and the behavioral evaluation were to evaluate the effect of 6-gingerol on IBS-D rats. Further, colonic epithelial cells (CECs) were collectted and to evaluate the effect of 6-gingerol on the expression of inflammatory factors and changes of NF-κB pathway. Results The IBS-D rat model was successfully established by chemical stimulation and acute and chronic pressure stimulation. And ginger treatment significantly reduced the defecation frequency, fecal water content and AWR scores in IBS-D rats. Histopathological analysis showed that ginger treatment can significantly reduce colonic edema and promote the recovery of inflammation in IBS-D rats, and the effect is equivalent to rifaximin. Elisa and RT-qPCR showed that ginger inhibited the expression of proinflammatory factors (TNF-α, IL-6, iNOS) in IBS-D rats. Western blot showed IkBα was up-regulated while p-p65 was inhibited under ginger treatment. HPLC analysis showed that 6-gingerol was the main component of ginger, which could improve clinical symptoms in IBS-D rats. Western blot and RT-qPCR showed that 6-gingerol inhibited the expression of proinflammatory factors (TNF-α, IL-6, iNOS) in CECs, and inhibition of IκBα degradation and phosphorylation of p65 involved in NF-κB pathway. Conclusion Ginger and ginger extract could relieve intestinal hypersensitivity of IBS-D by inhibiting proinflammatory response.

Total polysaccharides of adlay bran (Coix lachryma-jobi L.) improve TNF-α induced epithelial barrier dysfunction in Caco-2 cells via inhibition of the inflammatory response

2019 ◽  
Vol 10 (5) ◽  
pp. 2906-2913 ◽  
Author(s):  
Yanlong Li ◽  
Xudong Tian ◽  
Shengcai Li ◽  
Lijun Chang ◽  
Ping Sun ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Irritable Bowel Syndrome ◽  
Epithelial Barrier ◽  
Intestinal Epithelial ◽  
Barrier Dysfunction ◽  
Intestinal Epithelial Barrier ◽  
Tnf Α ◽  
Inflammatory Bowel ◽  
Irritable Bowel ◽  
Epithelial Barrier Dysfunction

Dysfunction of the intestinal epithelial barrier plays an important role in the pathogenesis of several intestinal diseases, including celiac disease, inflammatory bowel disease, and irritable bowel syndrome.

scholarly journals Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome

2013 ◽  
Vol 305 (8) ◽  
pp. G529-G541 ◽  
Author(s):  
Yehuda Ringel ◽  
Nitsan Maharshak
Keyword(s):  
Irritable Bowel Syndrome ◽  
Immune Function ◽  
Intestinal Microbiota ◽  
Clinical Symptoms ◽  
Current Evidence ◽  
Future Research ◽  
Gastrointestinal Microbiota ◽  
Plausible Model ◽  
Irritable Bowel ◽  
The Brain

The pathophysiology of irritable bowel syndrome (IBS) is believed to involve alterations in the brain-gut axis; however, the etiological triggers and mechanisms by which these changes lead to symptoms of IBS remain poorly understood. Although IBS is often considered a condition without an identified “organic” etiology, emerging evidence suggests that alterations in the gastrointestinal microbiota and altered immune function may play a role in the pathogenesis of the disorder. These recent data suggest a plausible model in which changes in the intestinal microbiota and activation of the enteric immune system may impinge upon the brain-gut axis, causing the alterations in gastrointestinal function and the clinical symptoms observed in patients with IBS. This review summarizes the current evidence for altered intestinal microbiota and immune function in IBS. It discusses the potential etiological role of these factors, suggests an updated conceptual model for the pathogenesis of the disorder, and identifies areas for future research.

IFN-γ and TNF-α decrease serotonin transporter function and expression in Caco2 cells

2007 ◽  
Vol 292 (3) ◽  
pp. G779-G784 ◽  
Author(s):  
Kevin F. Foley ◽  
Cristen Pantano ◽  
Allison Ciolino ◽  
Gary M. Mawe
Keyword(s):  
Ulcerative Colitis ◽  
Irritable Bowel Syndrome ◽  
Conditioned Medium ◽  
Human Lymphocytes ◽  
Protein Levels ◽  
Tnf Α ◽  
Ifn Γ ◽  
5 Ht Uptake ◽  
Irritable Bowel

Recent studies have shown that mucosal serotonin (5-HT) transporter (SERT) expression is decreased in animal models of colitis, as well as in the colonic mucosa of humans with ulcerative colitis and irritable bowel syndrome. Altered SERT function or expression may underlie the altered motility, secretion, and sensation seen in these inflammatory gut disorders. In an effort to elucidate possible mediators of SERT downregulation, we treated cultured colonic epithelial cells (Caco2) with conditioned medium from activated human lymphocytes. Application of the conditioned medium caused a decrease in fluoxetine-sensitive [3H]5-HT uptake. Individual proinflammatory agents were then tested for their ability to affect uptake. Cells were treated for 48 or 72 h with PGE2 (10 μM), IFN-γ (500 ng/ml), TNF-α (50 ng/ml), IL-12 (50 ng/ml), or the nitric oxide-releasing agent S-nitrosoglutathione (GSNO; 100 μM). [3H]5-HT uptake was then measured. Neither PGE nor IL-12 had any effect on [3H]5-HT uptake, and GSNO increased uptake. However, after 3-day incubation, both TNF-α and IFN-γ elicited significant decreases in SERT function. Neither TNF-α nor IFN-γ were cytotoxic when used for this period of time and at these concentrations. These two cytokines also induced decreases in SERT mRNA and protein levels. By altering SERT expression, TNF-α and IFN-γ could contribute to the altered motility and expression seen in vivo in ulcerative colitis or irritable bowel syndrome.

Sign in / Sign up

Export Citation Format

Share Document